A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
ConditionRheumatoid Arthritis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
Eligibility criteria
Qualifiers
Inclusion
Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening.
Moderately-to-severely active RA as defined by: a. >= 6 swollen joints on 66SJC and >= 6 tender joints on 68TJC; b. CRP > upper limit of normal.
Have a positive ACPA at screening.
Disqualifiers
None
Trial design
Treatments tested in this trial
- AZD1163
- Placebo
Treatment groups
320 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov